Synlogic (SYBX)

• Market cap: $12.3M
• 1 day: -5.41%
• 5 days: -0.94%
• 1 month: -37.87%
• 3 months: -36.36%
• 6 months: -13.22%
• Year to date: -26.06%
• 1 year: -29.53%
• 5 years: -96.96%
• 10 years: -99.87%
• Sector: Healthcare
• Industry: Biotechnology

About: Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Employees: 1